Open Actively Recruiting

Antibiotic Tumescent For Chronic Wounds


Brief Summary

Chronic non-healing wounds are becoming an increasingly more common problem. Eligible, consenting patients with chronic leg wounds will either continue to the standard of care or will be randomized to the treatment cohort where antibiotic solution will be injected in the area around the wound. All patients will continue standard wound care as dictated by the wound care clinic. Subjects of both the control and treatment will have approximately 6 study specific visits that may or may not coincide with previously schedule wound care clinic visits. As these specified visits wound size and healing will be documented and patients will complete surveys. The study will conclude for the subject after approximately 6 months. Again, these patients may continue standard wound care but will no longer have study obligations.

Primary Purpose
Study Type
Phase 2


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Inclusion Criteria:

  • Male or female ≥18 years of age.
  • Must have:
    • One or more full thickness ulcers on the lower extremity with a surface area exceeding 0.5 cm^2 (50 mm^2) and less than 10 cm^2 after debridement (full thickness means extending through the epidermis and dermis but not involving tendon, bone or joint capsule).
    • Presence of a chronic wound (including venous ulcer, arterial ulcer, pressure ulcer, diabetic foot ulcer, ischemic ulcer) that has existed for >4 weeks at Visit 1.
    • Documentation that the wound has been treated at least 2 times at the wound care center.
    • Documentation that the wound area has not decreased by more than 50% in 4 weeks.
    • Willing to provide written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.
  • Adequate perfusion as demonstrated by TcPO2≥40 mm Hg, ABI ≥ 0.7, or great toe pressure≥50 mm Hg, or palpable pulses of the lower extremity such as dorsalis pedis and/or posterior tibial artery.
  • In the opinion of the investigator, participants must be considered reliable, willing, and able to give signed informed consent in English and sign the informed consent form.
  • For participants of reproductive potential, two of the following forms of contraception are required between visits 1-4 (total of 3-6 weeks), one of which must be a barrier method:
    • Condoms (male or female) with or without a spermicidal agent
    • Diaphragm or cervical cap with spermicide
    • Intrauterine device (IUD)
    • Tubal ligation
    • Hormone-based contraceptive such as oral birth control pills

Exclusion Criteria:

  • Participants with limb threatening infection, extensive cellulitis (≥2 cm radially beyond the borders of the wound), lymphangitis, fasciitis, deep tissue infection, abscess, pus, osteomyelitis, or other evidence of local or systemic complications of infection.
    • Wound size/surface area, duration, severity, or location outside of INCLUSION criteria Note: Consideration will be given to minor variation, if deemed appropriate by the medical director, and authorized.
    • Clinically severe wound at high risk for amputation as determined by the Medical Director.
  • Cellulitis or acute infection as determined by:
    • Significant wound erythema, induration, warmth, presence of pus, or tenderness, determined by PI or medical director ≥ 2 cm radially from wound margin.
    • Fever with electronic temp >100.4°F (>38°C)
  • Following enrollment, if wound culture returns positive for Pseudomonas.
  • Participants with symptoms of systemic infection or uncontrolled diabetes mellitus (e.g., severe hyperglycemia, ketoacidosis, azotemia).
  • Participants who are allergic or have shown hypersensitivity to penicillin, cefazolin, other beta-lactams, the cephalosporin group of antibiotics, lidocaine, or to local anesthetics of the amide type.
  • Participants requiring intravenous antimicrobials during the study period for any infection, including diabetic foot ulcer. Mild localized infection that would be treated on an outpatient basis could be approved by Medical Director authorization.
  • Participants who are currently treated by dialysis, awaiting dialysis, or who have an estimated glomerular filtration rate of ≤ 30 mL/min/1.73 m^2.
  • Participants who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc., during the study period.
  • Participants with known active alcohol or substance abuse within the 6 months preceding study entry.
  • Participants who are receiving systemic corticosteroids (in a dose equivalent to ≥20 mg of prednisone per day), biologic therapy, immunosuppressants, , radiation therapy, or cytotoxic agents, unless approved by medical director authorization
  • Participants who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin, not involving the wound site).
  • Participants with acquired immune deficiency syndrome (AIDS) or known human immunodeficiency virus (HIV) positivity.
  • Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize participant safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).
  • Women who are breastfeeding, pregnant, or attempting to become pregnant.
  • Active acute medically unstable condition defined by:
    • Diabetes Mellitus Type 1 or 2, with A1C greater than 9.5. Consideration to HbA1c higher than 9.5 - 10.0% after consultation with the medical director or PI.
    • Unstable cardiovascular or other high-risk general medical condition making participation in the study a significant risk to the participant, per medical director determination.
    • Laboratory evidence of severe metabolic, renal, hepatic, endocrine, hematologic disorder per medical director determination.
    • Recent trauma complicated by significant bone, nerve, or vascular damage.
    • Sickle Cell Disease.
  • Participant is enrolled/participating in another study or does not agree to refrain from participating in another study while enrolled in this study.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Healthy Volunteers
Sean McCleary
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit